Platinum based chemotherapy

Phase 3Small molecule

Platinum based chemotherapy is one of 284 small molecule programs targeting Small Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

283

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell CarcinomaActive, not recruiting

Oropharynx CancerActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Bladder CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

Small Cell CarcinomaPhase 2

Active, not recruiting

Oropharynx CancerPhase 2

Active, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

Fallopian Tube CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Bladder CancerPhase 1/Phase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Cervical CancerPhase 3

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Platinum based chemotherapy

Roche

Phase 3

10 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

Lenvima

Eisai

Preclinical

6 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Remeron

OOrganon and Co

Preclinical

1 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

REGN2810

Regeneron

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Metastatic

NCT06236425

Q4 2026

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT05338970

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05657873

Q2 2027

Phase 1Active, not recruiting

Solid Tumor

NCT05614102

Phase 3Active, not recruiting

Cervical Cancer

NCT04906993

Q4 2027

Phase 2Recruiting

Neoadjuvant Chemoimmunotherapy

NCT06424899

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer10 trials

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05657873·68 enrolled

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Active, not recruiting·AArriVent BioPharma, Inc.·Phase 3·NCT05607550·398 enrolled

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Completed· Incyte logo

Incyte·Phase 2·NCT03322566·233 enrolled

Show 7 more trials

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03663166·19 enrolled

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07358689·120 enrolled

A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT00404703·37 enrolled

The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer

Recruiting·LLithuanian University of Health Sciences·N/A·NCT06000358·120 enrolled

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT06465329·120 enrolled

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab Based Regimen in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)

Recruiting· Regeneron logo

Regeneron··NCT05363319·500 enrolled

TROPION-Lung02: Datopotamab Deruxtecan Combo in NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05338970·740 enrolled

Ovarian Cancer3 trials

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Completed·TThe Christie NHS Foundation Trust·Phase 1·NCT02855697·28 enrolled

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Not yet recruiting·—·Phase 2·NCT07295132·160 enrolled

A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT02489006·71 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated· GSK logo

GSK·Phase 3·NCT04428333·117 enrolled

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

Unknown status·—·Phase 2·NCT05136768·50 enrolled

Lung Cancer2 trials

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Recruiting·GGenprex, Inc.·Phase 1/2·NCT04486833·158 enrolled

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Completed· Roche logo

Roche·Phase 4·NCT00451906·2,252 enrolled

EGFR Mutation1 trial

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Completed·YYuhan Corporation··NCT05862194·534 enrolled

14 more indications

Chemoradiotherapy1 trial

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Recruiting·—·Phase 3·NCT04821778·2,000 enrolled

Metastatic1 trial

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06236425·7 enrolled

Gut Microbiota1 trial

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Unknown status·SShanghai Zhongshan Hospital·Phase 1·NCT05008861·20 enrolled

Small Cell Carcinoma1 trial

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT00391586·45 enrolled

Immunotherapy1 trial

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT06623656·112 enrolled

Neoadjuvant Therapy1 trial

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

Recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06775275·60 enrolled

Bladder Cancer1 trial

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Terminated·XXennials Therapeutics Australia Pty Ltd·Phase 1/2·NCT04851834·12 enrolled

Cervical Cancer1 trial

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04906993·443 enrolled

Oropharynx Cancer1 trial

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT06234748·19 enrolled

PARP Inhibitor1 trial

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

Not yet recruiting·YYonsei University·Phase 2·NCT07340164·116 enrolled

Neoadjuvant Chemoimmunotherapy1 trial

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Recruiting·ZZeng Jian·Phase 2·NCT06424899·92 enrolled

Esophageal Cancer1 trial

Neoadjuvant Treatment Modalities in Esophageal Cancer

Recruiting·—·Phase 3·NCT04821843·2,000 enrolled

Solid Tumor1 trial

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Zeta Inhibitor (DGKzi) BAY 2965501 as Monotherapy, and in Combination, in Participants With Advanced Solid Tumors

Active, not recruiting· Bayer logo

Bayer·Phase 1·NCT05614102·284 enrolled

Metastatic Non Small Cell Lung Cancer1 trial

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Recruiting·NNovoCure GmbH·Phase 3·NCT06216301·734 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Platinum based chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platinum based chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platinum based chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Platinum based chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer10 trials

Ovarian Cancer3 trials

Head and Neck Squamous Cell Carcinoma2 trials

Lung Cancer2 trials

EGFR Mutation1 trial

Chemoradiotherapy1 trial

Metastatic1 trial

Gut Microbiota1 trial

Small Cell Carcinoma1 trial

Immunotherapy1 trial

Neoadjuvant Therapy1 trial

Bladder Cancer1 trial

Cervical Cancer1 trial

Oropharynx Cancer1 trial

PARP Inhibitor1 trial

Neoadjuvant Chemoimmunotherapy1 trial

Esophageal Cancer1 trial

Solid Tumor1 trial

Metastatic Non Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News